Evolus has signed an exclusive U.S. licensing agreement with IBSA to develop and commercialize Profhilo, a hybrid hyaluronic acid injectable positioned in the skin-quality and hydration segment. The 15-year term carries no upfront payment, with Evolus bearing development and commercialization costs.
Injectables
Evolus Secures Exclusive U.S. Rights to Profhilo From IBSA — 15-Year Term, No Upfront Fee
Evolus expands injectable portfolio into skin quality with IBSA's hyaluronic acid biostimulator.
Evolus takes on Profhilo under a 15-year exclusive U.S. license with zero upfront cost, betting on skin-quality market growth.
Profhilo occupies distinct territory from traditional fillers and neuromodulators—it's a high-concentration, low-volume HA formulation designed for superficial dermal hydration and collagen stimulation rather than volumization. For practices, this represents Evolus's move beyond Jeuveau (botulinum toxin) into the growing skin-quality category, competing directly with AbbVie's Juvéderm Hydro and Galderma's Restylane Vital. The licensing structure—no upfront, revenue-share model—suggests Evolus is betting on market expansion rather than immediate margin capture.
Source: original report ↗
Frequently asked questions
What is Profhilo and how does it differ from traditional dermal fillers?
Profhilo is a high-concentration, low-volume hyaluronic acid injectable designed for superficial dermal hydration and collagen stimulation, not volumization. Unlike traditional fillers that add volume to deeper layers, Profhilo works in the skin-quality segment to improve hydration and skin texture, positioning it closer to products like Juvéderm Hydro and Restylane Vital.
When will Profhilo be available in the U.S.?
The article does not specify a launch timeline for Profhilo in the U.S. Evolus has secured the exclusive 15-year licensing rights from IBSA, but development and commercialization timelines have not been announced.
What does Evolus's Profhilo deal mean for medspa practices?
This expansion gives practices another option in the skin-quality category beyond Evolus's existing Jeuveau neuromodulator. It allows Evolus to compete directly with AbbVie's Juvéderm Hydro and Galderma's Restylane Vital, potentially offering practices a new revenue stream in the hydration and biostimulation segment.
Why did Evolus structure the Profhilo deal with no upfront payment?
The revenue-share model with no upfront fee suggests Evolus is prioritizing market expansion and long-term growth over immediate margin capture. This structure allows Evolus to invest in development and commercialization while sharing risk with IBSA.
How long is Evolus's exclusive license for Profhilo in the U.S.?
Evolus has secured a 15-year exclusive licensing agreement with IBSA to develop and commercialize Profhilo in the United States.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.